About Abselion.
Simplifying complexity. Advancing discovery.
Abselion develops practical measurement tools that help scientists generate reliable, actionable data.
Based in Cambridge, UK, we create technologies that simplify biological measurements across life sciences, biotech, and therapeutic development. Our platform combines robust engineering, purpose-built assay formats, and intuitive software to streamline workflows and enable faster, more confident decisions – delivering high-quality data without the cost and complexity of traditional systems.
Our story.
Abselion was founded as a spin-out from the University of Cambridge, built on a shared belief that scientific measurement could be both rigorous and practical.
Motivated by the limitations of existing tools, our team set out to create a more accessible and efficient way to generate high-quality biological data.
Our first focus was on protein quantification, where fast, reliable insights are critical but often difficult to obtain. Since then, we’ve continued to expand our capabilities, always guided by the needs of real researchers and a commitment to making precision more practical.
Looking ahead.
As research challenges evolve, so do we.
Abselion is continuing to expand its offering, with new assays and formats in development and a long-term vision to support a broader range of measurement needs across the life sciences.
We remain focused on delivering tools that are scientifically rigorous, easy to use, and ready for the pace of modern research – whatever comes next.
Recognised innovation.
Abselion’s work has been recognised across the scientific, investment, and innovation communities for its approach to simplifying complex biological measurements.
Our technologies are built for real-world research combining intuitive workflows, purpose-built assays, and reliable performance to support confident decision-making.
This includes recognition from leading industry bodies, valued partners, and innovation-focused investors. As we grow, our focus remains on delivering practical innovation that drives faster, more reliable insights across life science and therapeutic development.
These awards reflect the strength of our technology, the focus of our team, and our commitment to delivering impactful tools that advance research, development, and real-world application.
Bioprocessing Industry Association – Next-Gen Analytics Award
2023
Awarded for Amperia’s impact on protein and viral particle quantification in bioprocessing workflows.
SLAS Innovation AveNEW – Top Startup Award
2021
Presented at ELRIG Drug Discovery for innovation in lab automation.
AMS Corporate Challenge – Winner, Next-Generation Medical Sensing
2020
Recognised for advances in next-generation medical sensing.
Royal Society of Chemistry – Emerging Technology Prize
2019
Winner in the “Materials and Enabling Technologies” category.
Meet the team.
We’re a multidisciplinary team of scientists, engineers, and industry professionals with a shared goal: to deliver practical tools that advance life science research.
From product development to customer partnerships, we combine deep technical expertise with commercial insight to drive real-world impact.
Our investors.
Led by globally respected investors in bioprocessing and life sciences. Each brought both capital and deep sector expertise – a strong validation of Abselion’s technology and market opportunity.
M Ventures
M Ventures is the strategic VC arm of Merck, one of the global leaders in bioprocessing through its MilliporeSigma division. Their lead role in Abselion’s Series A reflects deep alignment with the platform’s technical relevance and commercial potential.
“We believe Abselion’s technology can fundamentally improve how bioprocess analytics are delivered – enabling flexibility, speed, and access for a broader set of users.”
— Oliver Hardick, Investment Director, M Ventures
BioProcess 360 Partners
Founded by the former leadership of Purolite – a global leader in downstream bioprocessing, acquired by Ecolab for $4B – BP360 brings both operational expertise and strategic networks.
Chris Major, formerly Commercial Lead at Purolite, brings deep experience in bioprocess product commercialisation.
BGF (Business Growth Fund)
BGF has backed Abselion since its earliest funding rounds, providing continuity, strategic support, and deep expertise.
Investment Director Luke Rajah holds a PhD in Biophysics, and his previous research contributes to modern analytical technologies.
Untitled Ventures
Untitled Ventures specialises in backing disruptive deep-tech companies, particularly those scaling from Europe into global markets. Their focus spans therapeutic innovation, life-science tools, and synthetic biology.
Their participation in Abselion’s Series A reflects their support for practical technological innovation in bioprocessing and analytical instrumentation.
R42 Group
R42 supports disruptive, scientifically rigorous companies – aligned with Abselion’s vision of accessible innovation.
Their mission is to invent and fund world-changing science ventures – combining AI, life sciences, and ethics.
Interested in joining a dynamic and interdisciplinary team achieving amazing results?
We’re growing a company focused on solving real problems in life science research through practical innovation, thoughtful design, and close collaboration with the scientists we serve. If you’re excited by meaningful work and a team that values both rigour and impact, we’d love to hear from you.
